Active Ingredient: Amoxicillin, Clavulanic Acid
Dosage: 70 ml
Route of Administration: Oral
Dosage Form: Suspension
Quantity per package: 1
Availability: Out of stock
Ampliron Duo is a penicillin-type antibiotic used to treat a wide variety of bacterial infections. It works by stopping the growth of bacteria. This drug only treats bacterial infections. Currently, this suspension is unavailable. We offer you to surf our antibiotic category to find another antibiotic with the same properties.
Ampliron Duo is a broad-spectrum antibiotic. It is administered twice daily and is indicated for the short-term treatment of the following bacterial infections caused by amoxicillin-resistant β-lactamase producing microorganisms.
It is applied in the infections of the upper respiratory tract (including nose, throat, and ear), particularly recurrent tonsillitis, sinusitis, otitis media. These infections are frequently caused by:
- Streptococcus pneumoniae;
- Haemophilus influenzae;
- Moraxella catarrhalis;
- Streptococcus pyogenes.
Infections of the lower respiratory tract, particularly acute exacerbations of chronic bronchitis (especially if considered severe), bronchopneumonia are treated with this antibiotic. These infections are frequently caused by:
- Streptococcus pneumoniae;
- Haemophilus influenzae;
- Moraxella catarrhalis.
Urinary tract infections, particularly cystitis (especially when it is recurrent or complicated, excluding prostatitis) are treated with this antibiotic. These infections are frequently caused by:
- Enterobacteriaceae (mainly Escherichia coli);
- Staphylococcus saprophyticus;
- Enterococcus species.
Infections of the skin and soft tissues, especially cellulitis, wound infections and severe dental abscesses with disseminated cellulitis are treated with Ampliron Duo. These infections are often caused by:
- Staphylococcus aureus;
- Streptococcus pyogenes;
- Bacteroides species.
Mixed infections caused by amoxicillin-sensitive organisms and beta-lactamase-producing organisms sensitive to the amoxicillin-clavulanic acid combination can be treated with Ampliron Duo. These infections will not require another antibiotic.
Dosage and administration
Weight dose: 20-40 mg/kg/day divided into 2 doses (12 h). The recommended daily dose is:
- 25/3.6 mg/kg/day in mild to moderate infections (upper respiratory infections such as recurrent tonsillitis, lower respiratory system, and skin and soft tissue infections).
- 45/6.4 mg/kg/day for the treatment of more severe infections (upper respiratory infections such as otitis media and sinusitis, lower respiratory infections such as bronchopneumonia and urinary tract infections).
The dosage in children under 2 years will depend on body weight: In otitis media, sinusitis, lower respiratory tract infections, and more serious infections, 45 mg/kg/day every 12 hours is recommended. In less severe infections, 20 mg/kg/day is recommended every 12 hours.
Children with immature renal function: the use of this antibiotic is not recommended.
Renal impairment: in children with a glomerular filtration rate (GFR)> 30 ml/minute no dosage adjustment is required. In children with GFR
Hepatic impairment: dose with caution; monitor liver function at regular intervals. There is not enough evidence to establish a dosage recommendation so far.
Mode of administration: to minimize the potential gastrointestinal intolerance, take this antibiotic together with the meal. The treatment should not last for over 14 days. The treatment can be started parenterally and continued orally.
Amprilon Duo is contraindicated in patients with a history of hypersensitivity to penicillin, jaundice/liver dysfunction associated with penicillins or the administration of amoxicillin and clavulanic acid. Take the drug with caution in the case of cross-sensitivity with other β-lactam antibiotics, such as cephalosporins.
Changes in liver function tests have been observed in some patients treated with Amprilon Duo. The clinical importance of these changes is uncertain, but still, Amprilon Duo should be administered with caution in patients with evidence of liver dysfunction.
Rarely, cholestatic jaundice was observed, which can be severe but is usually reversible. Signs and symptoms may not be apparent until 6 weeks after the discontinuation of treatment.
In patients with moderate or severe renal impairment, the use of Amprilon Dou is not recommended. Severe and occasionally fatal hypersensitivity reactions (anaphylactoid) have been reported in patients treated with penicillin. These reactions are more likely in individuals with a history of penicillin hypersensitivity. Erythematous rashes associated with infectious mononucleosis have been observed in patients treated with amoxicillin.
Prolonged use may also occasionally result in excessive proliferation of non-sensitive organisms. Pseudo-membranous colitis has been reported, which can vary between mild to severe.
Overdose with Amprilon Duo is unlikely. If this happens, gastrointestinal symptoms and disorders of fluid and electrolyte balance may occur. They can be treated symptomatically, considering the aqueous/electrolyte balance. Hemodialysis is effective.
Long-lasting bleeding time and prothrombin time have been observed in some patients treated with Amprilon Duo.
This antibiotic should be used with caution in patients undergoing anticoagulant therapy. Like other broad-spectrum antibiotics, it may decrease the effectiveness of oral contraceptives. Concomitant use of allopurinol during treatment with amoxicillin may increase the likelihood of allergic skin reactions. There are no data on the concomitant use of Amprilon Duo and allopurinol.